Skip to main content
Gencurix Inc. logo

Gencurix Inc. — Investor Relations & Filings

Ticker · 229000 ISIN · KR7229000005 KO Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2022-03-14 Regulatory Filings
Country KR South Korea
Listing KO 229000

About Gencurix Inc.

https://www.gencurix.com/eng/

Gencurix Inc. is a molecular diagnostics company that develops and commercializes diagnostic solutions for precision medicine. The company's portfolio focuses primarily on oncology, offering prognostic, companion, and early detection tests. Key products include GenesWell BCT, a multigene prognostic test for early-stage breast cancer, and the GenesWell ddEGFR Mutation Test, a ddPCR-based companion diagnostic. Gencurix also utilizes its Droplex liquid biopsy platform for early cancer detection and develops diagnostic tests for infectious diseases. The company's core technologies include digital droplet PCR (ddPCR), real-time PCR, and liquid biopsy for analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Recent filings

Filing Released Lang Actions
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Gencurix) regarding a 'Single Sales/Supply Contract' amendment. It details the disclosure of a previously withheld counterparty name following the expiration of a confidentiality period. Since this is a specific regulatory disclosure regarding a contract update that does not fit into categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2022-03-14 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly labeled as a '정정신고' (Correction Report). It details changes to previously reported stock option grants, including adjustments to the number of shares and the responsible officer. This type of filing is a standard regulatory disclosure regarding capital structure and employee compensation instruments, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Remuneration Information' (which is for executive compensation packages).
2022-03-07 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from Gencurix regarding a significant change (over 30%) in sales or profit/loss structure. This is a standard disclosure requirement in the Korean market (DART system) when financial results deviate significantly from the previous period. It provides key financial highlights and reasons for the variance, which fits the definition of an Earnings Release (ER) as it is an initial announcement of financial results before the full audit report is finalized. FY 2021
2022-03-07 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement from Gencurix regarding the setting of a record date for the purpose of holding an Annual General Meeting (AGM). It specifies the record date (2021-12-31) and the reason (holding the 11th AGM). Since it is a brief regulatory notice regarding meeting preparation rather than the meeting materials themselves or a full report, it falls under the general regulatory filing category.
2021-12-15 Korean
기타경영사항(자율공시)(전환우선주 전환가액 조정)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system regarding the adjustment of the conversion price for convertible preferred shares due to a decline in the company's stock price. This type of disclosure relates to changes in the company's capital structure and potential future share issuance. Since it specifically details the adjustment of conversion terms for financial instruments (convertible preferred shares), it falls under the 'Capital/Financing Update' category.
2021-12-09 Korean
전환가액의조정(제5회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (CB) issued by Gencurix. It details the change in conversion price, the number of convertible shares, the reason for the adjustment (market price decline), and the calculation methodology. This falls under capital structure changes related to debt-to-equity instruments, which is classified as a Capital/Financing Update (CAP).
2021-12-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.